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Background: Many HIV-1-infected patients on suppressive antiretroviral therapy (ART) have transiently elevated HIV
RNA levels. The clinical significance of these viral blips is uncertain. We have determined the incidence of blips and
investigated important associations in the Swedish HIV-cohort.
Methods: HIV-1-infected ART naïve adults who commenced ART 2007–2013 were retrospectively included. Viral
blips were defined as a transient viral load between 50 and 500 copies/mL Subjects not suppressed after six
months on ART were excluded.
Results: Viral blips were found in 76/735 included subjects (10.3 %) and in 90/4449 samples (2.0 %). Median blip
viral load was 76 copies/mL (range 56–138). Median follow-up time was 170 weeks (range 97–240). Baseline viral
load was higher in subjects with viral blips (median log10 4.85 copies/mL) compared with subjects without blips
(median log10 4.55 copies/mL) (p < 0.01). There was a significant association between viral blips and risk for
subsequent virological failure (p < 0.001).
Conclusions: The Swedish national HIV-cohort has a low incidence of viral blips (10 %). Blips were associated with
high baseline viral load and an increased risk of subsequent virological failure.
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Most patients on combination antiretroviral therapy
(cART) reach the goal of therapy, HIV RNA < 50 copies/
mL blood, within three to six months after initiation of
cART [1, 2]. When quantified with more sensitive
methods, HIV can usually be detected in low concentra-
tions in almost all adherent patients on effective therapy.
The level of this so-called residual viremia has been dem-
onstrated to be between 1 and 10 copies/mL [3–5].
Even though the plasma viral load is suppressed to < 50
copies/mL in a majority of treated patients, it may in-
crease to detectable levels from time to time, usually to a
maximum of 500 copies/mL, before decreasing to < 50
copies/mL again, so called viral blips [6]. There may be* Correspondence: erik.sorstedt@vgregion.se
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(http://creativecommons.org/publicdomain/zeseveral reasons for these viral blips, including technical
errors or an influence of the type of blood collection tube
used [7]. Other explanations could be stochastic variations
[8], conditions that temporarily could lead to increased
HIV replication such as infections [9] or vaccinations
[10–12], and low drug concentrations in blood because of
poor adherence or poor absorption of antiretroviral drugs.
Prior studies have reported blip incidence between 13 and
40 % [13–16]. The large differences are due to different
blip definitions and viral load assays.
Possible consequences of viral blips are not clear.
Some studies have found a correlation between viral
blips and subsequent virological failure [17–20], whereas
others have not [8, 13, 14, 21–26]. The aim of this study
was to analyse the occurrence of viral blips in Swedish
HIV-1 infected individuals with modern cART, and to
find out whether any predictive factors could be identi-
fied between viral blips and variables such as nadir CD4le is distributed under the terms of the Creative Commons Attribution 4.0
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and some co-morbidities.
Methods
As part of clinical care, > 99 % of HIV-1-infected individ-
uals living in Sweden are followed from diagnosis and on-
wards using a clinical decision support tool, called InfCare
HIV. Clinical data from InfCare HIV is transferred in real
time to a research database. All demographic data, all HIV
RNA levels, all CD4+ T-cell counts, all ART regimens the
patient has ever been on, are registered in the database. In
this retrospective study, we included subjects matching
our inclusion criteria. Participants had to be HIV-1-
infected adults (≥18 years old) receiving their first line of
cART and they had to have been on treatment for at least
six months with at least one HIV RNA value < 50 copies/
mL to secure treatment response before data was col-
lected. The included patients were from five of Sweden’s
largest HIV-clinics (the Department of Infectious Diseases
at Karolinska University Hospital, Stockholm, Venhälsan
at Södersjukhuset, Stockholm, the Departments of Infec-
tious Diseases and Dermatology at Sahlgrenska University
Hospital, and the Department of Infectious Diseases at
Malmö University Hospital). These five clinics account for
approximately two thirds of all HIV-1-infected patients in
Sweden. Subjects were followed from August 2007 to De-
cember 2013 in two clinics (596 patients), and from June
2009 to December 2013 in the remaining three clinics
(139 patients). The different starting dates for inclusion
was because the ethylene diamine tetraacetic acid
(EDTA) test tubes and the highly sensitive COBAS Taq-
Man HIV-1 technique (CAP/CTM2; Roche, Molecular
Systems, Branchburg, NJ, USA), with a lower detection
limit of 40 and 20 copies/mL (version 1 and 2), respect-
ively, were introduced at different time-points at the
different clinics. All patients at these clinics are followed
according to the Swedish guidelines for treatment of HIV-
1 infection. After initiation of cART, plasma HIV RNA is
followed after 3 and 6 months, and after that every
third to sixth months depending on the patient and the
clinician.
Viral blips were defined as transient plasma HIV RNA
levels between 50 and 500 copies/mL preceded and
followed by HIV RNA < 50 copies/mL. Two values
within six weeks apart were interpreted as one isolated
blip where the highest HIV RNA level was noted. Pa-
tients were excluded if they had a viral failure, defined as
a single HIV RNA measurement > 500 copies/mL or two
consecutive samples ≥ 50 copies/mL drawn more than
six weeks apart. Treatment interruptions of shorter than
one month caused a pause in data collection for six
months from the reinitiation of ART. If the interruption
was longer than one month no more data was analysed
after the interruption. If the last registered sample was50–499 copies/mL this data was excluded to avoid con-
fusion between possible blips and viral failure.
Samples with HIV RNA levels between 20 and 50
copies/mL were registered separately unless they were
taken within six weeks from a blip and thus interpreted
as part of the transient viremia. Demographic and med-
ical data were collected, and included country of origin,
age, gender, source of transmission, ethnic background,
date of diagnosis and start of treatment, treating clinic,
baseline viral load (VL) sampled within one month before
treatment initiation, CD4 nadir, baseline primary drug-
resistance mutations, choice of cART, co-infections with
hepatitis B and/or C, and the presence or not of AIDS-
defining conditions. Treatment regimen was registered for
each blood sample during the study period.Statistical analysis
Mann-Whitney and chi-square tests were used for group
comparisons of continuous and categorical data, respect-
ively. Descriptive continuous data are presented as median
and interquartile range (IQR) while categorical variables
are listed as numbers and percentages unless otherwise
stated. Statistical analyses were performed using SPSS
(IBM Corp. Released 2011. IBM SPSS Statistics for Win-
dows, Version 20.0. Armonk, NY: IBM Corp.).
To deal with the repeated measurements we primar-
ily used Generalized Estimation Equations (GEE) with a
binary logistic link for both univariable and multivari-
able analysis. The association between blips and HIV
RNA measurement in the range between 20 and 50
copies/mL, sometimes referred to as low-level viremia
was evaluated by stratifying the subjects for the number
of samples below 50 copies/ml and then randomly
shuffling the blip indicator within each strata to achieve
an empirical distribution from which the significance
could be obtained. A similar procedure was used to
evaluate the association between failure and blips.Results
In total, 4449 blood samples from 735 HIV-1-infected
individuals were included (515 men and 224 women,
ages ranging from 22 to 81 years) (Fig. 1). Median
follow-up time was 170 weeks (range 97–240). Both
mean and median number of registered blood samples
per patient was 6 (range 1–22). Seventy-six out of the
735 patients had at least one episode with transient
viremia (Fig. 2), resulting in an incidence of 10.3 %. The
majority of subjects (63/76) had one blip, twelve subjects
had two blips, and one had three blips. HIV RNA levels
during the blips ranged from 50 to 443 copies/mL (median
76). Patient characteristics are shown in Table 1.
Baseline plasma HIV RNA levels were significantly
higher in patients with viral blips than in patients with
Fig. 1 Figure 1 shows all 735 included patients and 4449 samples analysed. The y-axis represents all included patients on stacked horizontal
lines (not included) depending on when they entered the study and the x-axis represents the study period. Each dot represents a blood
sample. Grey empty circles show HIV RNA < 50 copies/mL, red filled circles indicate a blip between 50 and 500 copies/mL and black filled
circles indicate viral failure
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copies/mL, respectively (p < 0.01) (Fig. 3).
Among the 659 patients who were suppressed during
the entire study period, 481 patients (73 %) had a con-
tinuous viral load under the detection threshold (HIV
RNA <40/20 copies/mL depending on assay version)
after the initial six months. Two hundred and thirty-four
patients (32 %, 366 samples) had at least one plasma
HIV RNA measurement between 20 and 50 copies/mL.
A significantly larger percentage of these samples were
found in the group with viral blips, 111 out of 603
(18.4 %), compared with 255 out of 3453 (7.4 %) samples
collected from suppressed patients (p < 0.0001). Twenty-
seven patients developed viral failure, 55.6 % due to con-
secutive samples > 50 copies/mL more then 6 weeks
apart and 44.6 % due to a single HIV RNA > 500 copies/
mL. The median HIV RNA among the last group was
1740 (range 662–12900) copies/mL. A significant correl-
ation was observed between viral failure and viral blips
(p = 0.005). The 27 patients with HIV RNA > 500 copies/
mL or 2 consecutive samples 50–500 copies/mL did not
have a significant higher baseline viral load. Twenty-six
of the 27 patients with viral failure were subsequently
re-suppressed, in 77 % without treatment alteration. One
patient was lost to follow-up after leaving the country.As expected, subjects with transient plasma viremia
had been sampled more frequently, in median nine times
compared with five times in suppressed subjects (p <
0.0001).
Transient viremia with HIV RNA between 50 and 500
copies/mL was seen in 90 out of 4449 samples (2.0 %).
There was a significant difference in blip incidence when
comparing different years after ART initiation, with the
highest incidence during the second year of observation
(Fig. 4a). There was, however, an even more significant
difference when comparing calendar years with a peak in
2011 (Fig. 4b). Calendar year and year after initiation are
by necessity confounded and when both are entered as
predictors in the statistical model only calendar year re-
mains significant (p = 0.0001).
There was no significant difference between subjects
with and without blips with respect to sex, AIDS-defining
diagnoses, co-infection with hepatitis B and/or C viruses,
number of primary drug resistance-associated mutations
or where they were treated.
Fifty-one per cent of the whole study population was on
a regimen containing a non-nucleoside reverse transcript-
ase inhibitor (NNRTI) and 42 % on a regimen containing
a ritonavir-boosted protease inhibitor (PI/r) (Table 2).
Only 0.5 % of the samples were registered while the
Fig. 2 Figure 2 shows patients with blips. The y-axis represents the 76 patients with registered viral blips on stacked horizontal lines (not in-
cluded) depending on when they entered the study and the x-axis represents the study period. Each circle represents a blood sample. Grey
empty circles indicate HIV RNA < 20 copies/mL, yellow filled circles low-level viremia (20–50 copies/mL), red filled circles a blip between 50 and
500 copies/mL, and black filled circles signal viral failure
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NRTI backbone, TDF/FTC was used in 66 % of the regis-
tered samples and ABC/3TC in the remaining one third.
The percentage of patients with blips on a PI/r-based
regimen was significantly higher than for subjects on a
NNRTI-based regimen, 2.8 % and 1.4 %, respectively
(p = 0.007 in the logistic model). The same pattern was
seen in patients with viral failure where the use of PI/r
was significantly more common (p = 0.001).
Variables from univariate analyses with p-values < 0.1
were entered in the multivariable analysis. This analysis




viral load <50 copies/mL
Number (%) 76 (10.3) 659 (89.7)
Age (years) 44.9 42.5
Male/Female 54/22 457/202
Baseline HIV RNA log10
(IQR)
4.85 (4.26–5.21) 4.55 (3.93–5.00)
AIDS (%) 12 (15.8) 59 (9.0)
HBV co-infection (%) 1 (1.3) 30 (4.6)
HCV co-infection (%) 7 (9.2) 59 (9.0)regimen, and baseline VL were all predictors for viral
blips (Table 3).Discussion
Viral blips are defined as transient episodes of detectable
viremia in patients on suppressive cART within a given
timeframe. There is no generally accepted definition of
the upper limit of a viral blip. We defined viral blips as
plasma HIV RNA between 50 and 500 copies/mL within
a time period of six weeks. The upper limit of 500 cop-
ies/mL was chosen because viral loads above this level
have been associated with treatment failure [19, 27].
Some studies have, however, reported an increased risk
of viral failure with transient viremia with a magnitude
less than 500 copies/mL [6, 26] and others found no cor-
relation at all between viral failure and the magnitude of
the blips [23]. The upper limit of viral blips in various
studies varies from 400 to 2000 HIV RNA copies/mL.
Viral loads higher than the upper limit defining a viral
blip have usually been considered viral failures [28]. In
clinical practise, it is of course very important to distin-
guish between harmless viral blips and potentially harm-
ful virological failure, where the latter most likely will
lead to a change in ART regimen.











Fig. 3 Pre-treatment viral load in subjects with and without viral
blips. Line indicates median log10 HIV RNA
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what is a blip or not, there is also the time aspect. When
elevated viral loads are found in two consecutive sam-
ples drawn within a short timeframe, they are most
likely part of a single blip [29]. To separate viral blips
from emerging virological failure we chose an interval of
six weeks to be considered as a solitary blip. We hypoth-
esized that this would be an appropriate time for a blip
to emerge and subside.
The different definitions of viral blips and use of
different quantification assays make comparisons be-
tween studies of viral blips difficult. Thus, when viral
blips in the range 50–500 copies/mL were quantified
with three different methods (Versant HIV-1 RNA 1.0
kPCR (Siemens), Abbot Realtime HIV-1, and COBAS
Ampliprep/COBAS TaqMan HIV-1 v 2.0 (Roche) as-
says), only 19 % of the detected viral blips could be
reproduced with any of the other methods [30].
We found an incidence of viral blips of 10 % in our
Swedish cohort. Older studies have found an incidence
of 33–40 % using assays with higher quantification limits
[13, 14]. In a more recent study where the same quanti-
fication method as in our study was used, but with the
upper limit of a viral blip defined as 200 copies/mL, the
incidence of blips was 38.1 % [15]. If the same definition
was applied to our material, only 69 patients (9.4 %)
would have had registered blips. Another recent study
reported blip incidence of 13 % but since they used dif-
ferent viral load assays a direct comparison is not pos-
sible [16]. The differences between our and other resultsare probably in part due to differences in frequency of
plasma viral load sampling, which was not presented in
the latter study. More frequent sampling increases the
probability of detecting a viral blip and patients with
viral blips are in addition more likely to be sampled
more often, at least in close proximity to a viral blip. It
can therefore be helpful to not only analyse the number
of patients with blips, but also the proportion of blood
samples containing blips [28]. One study using the older
reverse transcriptase PCR assay with 50 copies/mL as
lower limit of detection found viral blips in 3.6 % of the
blood samples [8]. The same assay was used in another
study where they separated patients with primary- from
chronic infection and found ratios of 6.0 % and 13.3 %,
respectively [31]. The lowest incidences of reported viral
blips are between 1.47 % in a high- and 1.64 % in a low/
middle-income cohort [32]. It is not possible to draw
any conclusions from these results, however, since there
is no information about the quantification methods that
were used.
Baseline VL was significantly higher in subjects with
blips (median 4.85 log10 copies/mL) than in suppressed
patients (4.55 log10 copies/mL). This is in accordance
with findings obtained by older quantification assays
[27, 31, 33] and from a recent study where different,
not specified, viral load assays were used [16]. The cor-
relation between high pre-treatment viral loads and
viral blips is perhaps not unexpected. It is well known
that ART is effective in suppressing but not eliminating
HIV-infection. Almost all patients who are on cART
have residual low-level viremia, approximately 1–10
HIV RNA copies/mL plasma [4, 5, 34–36], and the level
of residual viremia has been demonstrated to correlate
with pre-therapy plasma HIV RNA levels [3, 37, 38].
Even in patients who have been on suppressive ART for
more than ten years, there is an increased risk of viral
blips in those with high baseline HIV RNA levels [39].
There is strong evidence that persistent low level
viremia in patients on ART is derived from reservoirs of
long-lived virus-producing cells that are not affected by
currently available drugs that target new cycles of viral
replication [35, 40–43]. Viral blips were significantly
more common in patients on a boosted PI-based regi-
men than in patients on an NNRTI-based regimen. This
is in line with several other reports, but the opposite has
also been found [27, 38, 44, 45]. Possible explanations
for why viral blips could be more common in patients
on PIs are tolerability issues, which may affect adherence
and pharmacokinetic aspects including penetration to
sanctuary compartments. There can also be a selection
bias between PI- and NNRTI-based regimens such that
clinicians are inclined to choose a PI-based treatment
for patients with advanced disease or where low adher-























Fig. 4 Columns represent the percentage of HIV RNA samples 50–500 copies/mL in comparison to the total number of HIV RNA analysed per
year since data collection started (a) and in comparison to calendar year (b). The first sample in each subject is removed since it is below 50
copies/mL by inclusion criteria
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the non adherence and the secondary possibility of viral
replication in sanctuary sites that is the relevant factor.
The origin of viral blips is still uncertain but probably
multifactoral. As for low-level residual viremia, it has
been hypothesised that blips are caused by virus released
from long-lived cell populations. Other theories are that
viral blips are caused by continuous viral replication in
“sanctuary sites” with suboptimal drug concentrations
despite systemic effective ART and latent reservoirs with
productively infected CD4+ T cells and macrophages
with a very low cell turnover speed that occasionally
shed virions [34, 46–48].Table 2 HIV RNA levels and ART
HIV RNA <20 copies/mL HIV
Number of HIV-RNA samples (%) 3966 (89.1) 366
Blip HIV RNA copies/ml [median (IQR)] - -
NNRTI (%) 2083 (52.5) 163
PI (%) 1625 (41.0) 175
Others (%) 258 (6.5) 28One of the most important questions is whether
there are any consequences of viral blips, particularly
development of subsequent viral failure. We found a
significant association between viral blips and viral fail-
ure (p = 0.005) in accordance with another study [49].
Most likely the majority of the detected cases with viral
failure in this study represents treatment interruptions
due to adherence issues, especially when more then
two thirds were subsequently normalised without treat-
ment alteration. We believe that consecutive HIV
RNA > 50 copies/mL more likely represent an actual
treatment failure than a single HIV RNA > 500 copies/mL.
In some cases however the HIV RNA dynamics causeRNA 20–50 copies/mL HIV RNA 50–500 copies/mL Viral failure
(8.2) 90 (2.0) 27 (0.6)
76 (55.3–137.8) -
(44.5) 33 (36.7) 5 (18.5)
(47.8) 51 (56.7) 21 (77.8)
(7.7) 6 (6.7) 1 (3.7)
Table 3 Uni- and multivariable analyses
Univariable Multivariable
OR (95 % CI) p OR (95 % CI) p
Year <0.001 <0.001
2013 1 1
2012 2.2 (0.9–5.3) 0.07 2.1 (0.9–5.1) 0.09
2011 6.4 (3.0–14) <0.001 6.2 (2.9–13) <0.001
2010 3.7 (1.6–8.5) 0.002 3.5 (1.5–8.1) 0.003
Treatment 0.03 0.057
NNRTI 1 1
PI 1.9 (1.2–3.1) 0.007 1.8 (1.1–2.8) 0.017
Other 1.4 (0.6–3.2) 0.4 1.3 (0.6–3.0) 0.5
Baseline VL
(log10 HIV RNA)
1.4 (1.1–1.8) 0.007 1.4 (1.1–1.8) 0.005
CD4 nadir 1.0 (1.0–1.0) 0.14
Age (years) 1.0 (0.99–1.02) 0.6
Female 0.8 (0.5–1.4) 0.5
HBV 0.6 (0.1–3.9) 0.6
HCV 1.5 (0.6–3.3) 0.4
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single peak despite more than 6 weeks apart. Others
with several months between the sampling could be
due to recurrent blips where infrequent sampling fail
to detect re-suppression between the events.
Blip magnitude > 200 HIV RNA copies/mL in adherent
patients has been associated with a higher risk of viral re-
bound [6]. Although the opposite has been shown in older
studies [8, 13, 21, 22, 25, 26] this might be regarded as an
indication to monitor patients with viral blips more
closely. Since this is not a prospective study, no causality
between blips and viral failure can be proven.
Subjects with viral blips in this study also had a signifi-
cantly higher incidence of HIV RNA levels in the range
20–50 copies/mL compared with those without blips.
This might reflect that patients with high baseline HIV
RNA levels, and a large viral reservoir, are more prone
to release virus from this reservoir now and then, in the
range 20–50, as well as in the range 50–500 copies/mL.
It might, however, also be due to overall infrequent sam-
pling, reflecting that the values between 20 and 50 cop-
ies/mL are actually the start or tail of missed blips. This
low-level viremia has no clinical importance that we
know today, but some experts advocate that HIV RNA
levels less than 20 copies/mL should be the new cART
virological goal based on a study where a correlationbetween low level viremia and virological rebound was
found.
Patients initiating ART are more closely monitored
during the first year on treatment than later on. Pa-
tients with unexpected increases in plasma viral loads
are sampled more frequently in order to determine the
nature and course of the viremia. Mapping the natural
course of a viral blip would require frequent, perhaps
daily, blood sampling of patients, which for obvious
reasons is not done in clinical practice. In a patient
with unexpected viremia, a new viral load is usually
checked within one to three months depending on the
magnitude of the increase. By the time of the subse-
quent blood sampling, the viral load is often undetect-
able again. Blood sampling as often as every 2–3 days
of patients with blips has been performed in one study
with 10 patients [8]. Nine out of ten participants had
at least one blip during the 3–4 months the study was
conducted. These results are different from other
studies but they represent a limited population from a
short observation time and it has been suggested that
they represent stochastic statistical and biological vari-
ations [28].
Our study has some limitations. First of all, it is a
retrospective study and sampling has therefore been
based on clinical guidelines and decisions. Patients are
asked about adherence at every visit to the clinics, but
data on adherence has not been documented in a stan-
dardized way and antiretroviral drug concentrations have
not been measured. Poor adherence has been associated
with more frequent viral blips in one study [25], but not
in others [8, 16, 50]. It is not unlikely that patients
missing some doses could have suboptimal plasma anti-
retroviral drug concentrations which could lead to sub-
sequent viral replication, but poor adherence is probably
not the only explanation for viral blips as noted in in a
recent study from a highly adherent population [16].
The highest percentage of viral blips was found dur-
ing the second year after ART initiation (3.2 %). In the
multivariat analysis the strong correlation between viral
blips and year on treatment is caused by calendar year,
which was unexpected. A prior study demonstrated
that switching from COBAS TaqMan v1.0 to v2.0, as
was the case in this study, resulted in a increased num-
ber of detected HIV RNA levels that the researchers
concluded was the result of increased sensitivity due to re-
duced underquantification [51]. Upgrading to COBAS
Taqman v2.0 thus theoretically would increase the num-
ber of reported blips and not the opposite.. PCR master
mix batches are known to have some inter-variability but
since they are regularly switched and compared to a kit in-
dependent control they are unlikely the source of decreas-
ing blip incidence. Treatment guidelines did not undergo
any radical changes during these years and there has not
Sörstedt et al. BMC Infectious Diseases  (2016) 16:305 Page 8 of 9been a substantial change in our patient population. One
contributing factor to the decreasing frequency of viral
blips could be the overall improved treatment results that
we see in Sweden and in other countries. In a review, Fung
et al showed that studies based on clinical data tended to
have more frequent sampling during the first part of the
trials with the consequence that possible blips are missed
later because of limited testing [28].
Conclusions
The Swedish national HIV-cohort has a low incidence of
viral blips (10 %). Blips were associated with high base-
line viral load and an increased risk of subsequent viro-
logical failure. More data is needed to determine the
clinical relevance of this phenomenon and further stud-
ies would benefit from harmonised definitions.
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